Month: September 2026

Fezolinetant and Hot Flashes: How Non-Hormonal Menopause Drugs Work

Hot flashes are often described as a consequence of “low estrogen.” That is only part of the story.

The menopause transition also changes the brain circuits responsible for temperature regulation. Fezolinetant targets one of those pathways directly, providing a treatment for hot flashes and night sweats without supplying estrogen or another hormone.

In the United States, fezolinetant is FDA-approved for moderate to severe vasomotor symptoms caused by menopause. It is a neurokinin 3 (NK3) receptor antagonist and works differently from menopausal hormone therapy. Clinical trials show that it can reduce the frequency and severity of hot flashes, but it requires liver-function monitoring because rare serious liver injury has been reported. (U.S. Food and Drug Administration⁠)

Why Do Hot Flashes Happen?

Hot flashes and night sweats are collectively known as vasomotor symptoms.

They are linked to changes in the brain’s thermoregulatory system during the menopause transition. As estrogen levels change, signalling involving neurokinin B becomes disrupted within brain pathways involved in temperature control.

This effectively narrows the body’s thermoneutral zone—the temperature range within which the body does not need to actively cool or warm itself.

A relatively small change in core temperature can then trigger a disproportionate response: sudden heat, flushing, sweating and sometimes a subsequent chill.

This helps explain why a hot flash can appear to come from nowhere, including while sitting still or sleeping.

How Does Fezolinetant Work?

Fezolinetant does not replace estrogen.

It blocks neurokinin 3 receptors, which are involved in the signalling pathway controlling body temperature.

By reducing neurokinin B activity at these receptors, fezolinetant helps restore balance within the brain’s temperature-control system. The FDA describes this mechanism as addressing the altered balance between estrogen and neurokinin B signalling that occurs with menopause. (U.S. Food and Drug Administration⁠)

This makes fezolinetant fundamentally different from hormone therapy.

Menopausal hormone therapy acts through hormone receptors and can treat several estrogen-related menopausal symptoms. Fezolinetant targets the neurological pathway underlying vasomotor symptoms specifically.

It is therefore better understood as a targeted non-hormonal hot-flash treatment, not a non-hormonal version of HRT.

How Effective Is Fezolinetant?

Large phase 3 trials have shown clinically meaningful reductions in moderate to severe vasomotor symptoms.

In the SKYLIGHT 1 trial, women aged 40 to 65 experiencing an average of at least seven moderate to severe hot flashes each day were randomly assigned to placebo or fezolinetant.

At the US-approved 45 mg dose, fezolinetant produced significantly greater reductions in hot-flash frequency than placebo at both four and 12 weeks. Improvements were already evident after the first week and were maintained through the longer treatment period. (PubMed⁠)

SKYLIGHT 2 produced similar findings, with significant reductions in both frequency and severity of vasomotor symptoms compared with placebo. (PubMed⁠)

A later phase 3b trial specifically studied 453 women for whom hormone therapy was considered unsuitable because it was contraindicated, required caution, had previously been discontinued, or was something they chose not to use. Fezolinetant again reduced vasomotor symptoms compared with placebo. (PubMed⁠)

These findings matter because non-hormonal treatment is not required only by women who medically cannot take hormones. Some women simply prefer another option.

How Quickly Can It Work?

Clinical trials detected improvement within the first week of treatment.

That does not mean every woman will experience the same response or that symptoms disappear completely.

Treatment trials measure average changes across groups. Individual responses can range from substantial improvement to limited benefit.

The useful question is therefore not whether fezolinetant “stops hot flashes,” but whether it reduces their frequency or severity enough to meaningfully improve daily life or sleep.

Who Might Consider a Non-Hormonal Treatment?

There are several reasons a woman experiencing moderate to severe vasomotor symptoms might discuss a non-hormonal prescription treatment with her healthcare professional.

Some women have medical circumstances that make systemic menopausal hormone therapy inappropriate or require more careful risk assessment.

Others experience side effects with hormone therapy, do not obtain adequate symptom relief, or simply do not want to use hormones.

Fezolinetant expands the available choices because it treats vasomotor symptoms through a different biological pathway.

That does not make it inherently safer or more appropriate than hormone therapy for every woman. The two approaches have different benefits, risks, contraindications and treatment targets.

The decision should be individual.

Experiencing hot flashes, night sweats or other menopause symptoms? Join Sistapedia® free to explore trusted menopause information and discover verified healthcare professionals and Experts.

What Does Fezolinetant Not Treat?

This distinction is important.

Fezolinetant is FDA-approved specifically for moderate to severe vasomotor symptoms due to menopause. (U.S. Food and Drug Administration⁠)

It should not be assumed to treat every symptom associated with menopause.

For example, genitourinary syndrome of menopause can involve vaginal dryness, irritation, painful sex and urinary symptoms related to estrogen deficiency in genital and urinary tissues. Those symptoms have their own treatment options.

Similarly, osteoporosis prevention and treatment involve a different clinical decision.

A woman experiencing several menopause-related problems may therefore need a treatment strategy addressing more than hot flashes alone.

This is one reason medication choice should begin with identifying which symptoms actually require treatment.

Why Is Liver Monitoring Required?

This is now one of the most important considerations for women taking fezolinetant in the United States.

In 2024, the FDA strengthened its safety warning after receiving a post-marketing report of serious liver injury in a patient taking fezolinetant. The agency subsequently added a Boxed Warning, its most prominent safety warning, for the risk of rare but serious liver injury. (U.S. Food and Drug Administration⁠)

The FDA requires liver blood tests before treatment begins.

Under current US guidance, healthcare professionals should then perform hepatic laboratory testing monthly for the first three months, followed by testing at months six and nine. (U.S. Food and Drug Administration⁠)

Fezolinetant should not be started if certain baseline liver-test results are already sufficiently elevated.

This monitoring requirement is not an optional extra. It is part of the medicine’s current safety framework.

What Symptoms of Liver Injury Should You Know?

The FDA advises patients taking fezolinetant to stop the medicine immediately and contact the prescribing healthcare professional if symptoms suggesting liver injury develop.

These can include unusual fatigue, nausea, vomiting, itching, light-colored stools, dark urine, yellowing of the skin or eyes, abdominal swelling or pain in the upper-right abdomen. (U.S. Food and Drug Administration⁠)

These symptoms do not automatically mean liver injury has occurred.

But they should not be ignored or left until the next scheduled blood test.

The post-marketing case that prompted stronger FDA action developed symptoms within approximately 40 days of starting treatment, reinforcing why both laboratory monitoring and symptom awareness matter. (U.S. Food and Drug Administration⁠)

What Are the Other Side Effects?

Like any prescription medicine, fezolinetant can cause adverse effects.

The FDA lists common adverse reactions including abdominal pain, diarrhea, insomnia and back pain. (U.S. Food and Drug Administration⁠)

Clinical trials provide broader safety information. A pooled analysis of three phase 3 studies included more than 3,000 participants exposed to placebo or fezolinetant and evaluated treatment-emergent adverse events and liver-test abnormalities over treatment periods extending to 52 weeks. (PubMed⁠)

However, clinical trials cannot identify every rare adverse effect before a medicine reaches a much larger population.

That is why post-marketing surveillance matters. The liver warning is a clear example of safety information evolving after approval.

Fezolinetant Versus Hormone Therapy: Is One Better?

There is no universal winner.

Menopausal hormone therapy remains an important evidence-based treatment for appropriate women experiencing bothersome menopausal symptoms. Fezolinetant provides another mechanism for treating vasomotor symptoms without administering hormones.

The appropriate comparison depends on the individual woman.

Questions include which symptoms need treatment, medical history, contraindications, personal treatment preferences, medication interactions and willingness to undertake ongoing liver monitoring.

The presence of a non-hormonal option should not be interpreted as evidence that hormone therapy is inherently unsafe.

Likewise, being eligible for hormone therapy does not mean a woman must choose it.

The value of newer treatments is greater choice based on individual clinical circumstances.

When to Seek Medical Assessment

Hot flashes are common during perimenopause and menopause, but not every episode of unexplained sweating or flushing should automatically be attributed to menopause.

Seek medical assessment when symptoms are new, unusual, severe, accompanied by other unexplained symptoms, or the diagnosis is uncertain.

If you are considering fezolinetant, a healthcare professional needs to assess whether the medicine is appropriate and arrange required baseline liver testing.

If you are already taking it, follow the prescribed monitoring schedule and seek prompt medical advice for symptoms potentially suggesting liver injury.

Do not stop prescribed menopause treatment or switch therapies solely on the basis of general information online unless urgent medication safety instructions specifically tell you to stop.

A New Way to Think About Hot Flashes

Fezolinetant represents more than another menopause medication.

It reflects a more detailed understanding of why vasomotor symptoms happen.

Hot flashes are not simply the body noticing that estrogen has fallen. They involve altered signalling within neural circuits regulating temperature, and those circuits can now be targeted pharmacologically without replacing estrogen.

That creates a genuinely different treatment pathway.

But “non-hormonal” should never be mistaken for “risk-free.”

Fezolinetant can provide meaningful symptom reduction, while its current US prescribing framework also requires women and clinicians to take liver safety seriously.

The useful question is not whether hormonal or non-hormonal treatment is universally better.

It is which treatment best matches your symptoms, medical history, risk profile and preferences—and what monitoring that treatment requires.

FAQs

Is fezolinetant a hormone?

No. Fezolinetant is a non-hormonal neurokinin 3 receptor antagonist. It targets a brain signalling pathway involved in temperature regulation rather than supplying estrogen. (U.S. Food and Drug Administration⁠)

What is fezolinetant approved to treat?

In the United States, it is FDA-approved to treat moderate to severe vasomotor symptoms—hot flashes and night sweats—caused by menopause. (U.S. Food and Drug Administration⁠)

How quickly does fezolinetant work?

Phase 3 clinical trials found improvements in vasomotor symptoms within the first week, with benefits maintained during longer treatment. Individual responses vary. (PubMed⁠)

Why do I need blood tests while taking fezolinetant?

Rare serious liver injury has been reported. The FDA requires liver testing before treatment, monthly for the first three months, and again at months six and nine. (U.S. Food and Drug Administration⁠)

Is fezolinetant better than HRT?

Not universally. They work differently and have different benefits, risks and clinical uses. Treatment should be selected according to symptoms, medical history and individual preferences.

Continue on Sistapedia®

For Sistas: Join Sistapedia® free to explore trusted information across menopause and women’s reproductive health. Complete free Pink Tick identity verification to participate as a genuine identity-verified Sista and share your experience if you choose.

For healthcare professionals and Experts: Establish your professional presence and contribute evidence-informed education across Sistapedia®. Eligible Medical Doctors, Doctors of Osteopathic Medicine, General Practitioners, Registered Nurses, Healthcare Practitioners and Experts can apply for Crown Verification through the Verification tab in their profile.

Sources

U.S. Food and Drug Administration — FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause. (U.S. Food and Drug Administration⁠)

Lederman S, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. The Lancet. 2023. (PubMed⁠)

Schaudig K, et al. Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial. BMJ. 2024. (PubMed⁠)

Pooled phase 3 safety analysis of SKYLIGHT 1, SKYLIGHT 2 and SKYLIGHT 4. (PubMed⁠)

Medical disclaimer: This article provides general educational information and does not replace personalised medical advice, diagnosis or treatment. Speak with an appropriately qualified healthcare professional about symptoms, medicines, tests or treatment decisions.

Does Menopause Raise LDL Cholesterol? What Changes in Midlife

A cholesterol result that was previously normal can look different in your 40s or 50s—even when your diet has not dramatically changed.

Age contributes, but it is not the whole explanation. Research tracking women through midlife shows that the menopause transition itself is associated with changes in blood lipids, including increases in LDL cholesterol.

Menopause can contribute to rising LDL cholesterol, particularly during late perimenopause and early postmenopause. Hormonal and metabolic changes occur alongside ageing, changes in body composition and other cardiovascular risk factors. An increased LDL result should therefore be interpreted as part of your overall cardiovascular risk rather than dismissed as simply “normal for menopause.” (professional.heart.org⁠)

What Is LDL Cholesterol?

Cholesterol is a waxy substance the body needs to make cell membranes, hormones and other essential substances.

Because cholesterol cannot travel freely through blood, it is transported in particles called lipoproteins.

Low-density lipoprotein cholesterol (LDL-C) is commonly called “bad cholesterol” because higher concentrations contribute to cholesterol accumulation within artery walls and the development of atherosclerosis.

Over time, atherosclerotic plaque can narrow arteries and increase the risk of cardiovascular events including heart attack and stroke.

LDL is therefore not merely a number on a pathology report. It is one of the major modifiable factors clinicians use when assessing long-term cardiovascular risk. (American Heart Association⁠)

What Happens to LDL Around Menopause?

One of the strongest sources of evidence comes from the Study of Women’s Health Across the Nation, or SWAN, which followed thousands of women through the menopause transition.

The research found that total cholesterol, LDL cholesterol and other lipid measures increased particularly around late perimenopause and early postmenopause.

The American Heart Association’s scientific review of menopause and cardiovascular health concluded that increases in LDL-C and apolipoprotein B during midlife appear to be driven more strongly by the menopause transition than by chronological ageing alone. (professional.heart.org⁠)

That distinction matters.

A woman may be getting older at exactly the same time she is transitioning through menopause, so separating the effects is difficult. Longitudinal studies that follow the same women over time help researchers distinguish changes associated with reproductive ageing from those associated with ageing more generally.

The evidence suggests both matter—but menopause has an independent role.

Why Can Menopause Affect Cholesterol?

Estrogen interacts with multiple systems involved in cardiovascular and metabolic health.

During perimenopause, estrogen does not simply decline smoothly. Levels fluctuate considerably before becoming persistently lower after menopause.

At the same time, women can experience changes in body composition, including greater accumulation of visceral abdominal fat and reductions in lean mass.

These changes can affect lipid metabolism and insulin sensitivity.

The result is not one universal menopause cholesterol pattern. Some women experience substantial changes while others have relatively small shifts.

Genetics, diet, physical activity, body composition, smoking, diabetes, thyroid disease, medications and existing cardiovascular conditions can all influence the final result.

Menopause should therefore be viewed as one contributor—not an explanation for every elevated LDL result.

Is High LDL Just a Normal Part of Menopause?

No.

A change may be common without being clinically irrelevant.

Higher LDL increases exposure of arteries to atherogenic cholesterol over time. The updated 2026 US dyslipidemia guideline emphasises reducing lifelong exposure to plaque-forming lipoproteins and assessing cardiovascular risk earlier rather than waiting for disease to develop. (professional.heart.org⁠)

This makes midlife an important time to review cholesterol rather than accept worsening numbers as inevitable.

The Menopause Society similarly recommends attention to cholesterol alongside blood pressure, smoking, diabetes and other cardiovascular risk factors during and after menopause. (Menopause Society⁠)

The relevant question is not:

“Is this cholesterol rise normal for menopause?”

It is:

“What does this LDL level mean for my cardiovascular risk?”

LDL Is Only Part of Your Lipid Profile

A standard lipid panel usually provides more than LDL cholesterol.

It can include total cholesterol, HDL cholesterol and triglycerides, with non-HDL cholesterol also calculated or reported.

These measurements provide different information.

Historically, HDL has been described as “good cholesterol,” but cardiovascular risk assessment is more complicated than assuming higher HDL automatically offsets elevated LDL.

Research across the menopause transition has shown that the relationship between HDL and cardiovascular risk can change during midlife, meaning a high HDL result should not automatically reassure someone whose other risk factors are elevated. (professional.heart.org⁠)

Newer cardiovascular guidance also gives greater attention to additional markers in selected patients, including apolipoprotein B and lipoprotein(a).

These are separate topics from routine LDL assessment, but they illustrate why modern cardiovascular risk evaluation increasingly looks beyond total cholesterol alone.

Midlife health is about more than managing menopause symptoms. Create your free Sistapedia® profile to explore trusted menopause and cardiovascular-health information and discover verified reproductive-health professionals.

Should You Have Your Cholesterol Checked During Perimenopause?

Cholesterol screening is recommended throughout adulthood according to age, health history and national guidelines.

Perimenopause provides an additional reason to make sure cardiovascular risk has not been overlooked.

A 2026 analysis of US population data found that perimenopausal women were twice as likely to have a low overall cardiovascular-health score as women still experiencing regular menstrual cycles, with higher cholesterol and blood glucose contributing substantially to the difference. (American Heart Association⁠)

This does not mean every woman suddenly becomes high-risk during perimenopause.

It means the transition provides a useful checkpoint.

Blood pressure, cholesterol, blood glucose, smoking, physical activity, family history, body composition and reproductive history can all contribute to the broader picture.

What About Early Menopause?

The age at which menopause occurs can also matter.

Menopause occurring earlier than expected is associated with greater cardiovascular risk later in life. The 2026 US cholesterol guideline specifically recognises early menopause as a reproductive risk marker that can help personalise cardiovascular-risk assessment. (American Heart Association⁠)

That does not mean early menopause guarantees cardiovascular disease.

It means reproductive history can provide information that conventional risk factors alone may miss.

This is particularly relevant for women whose menopause occurred prematurely or after surgical removal of the ovaries.

Those situations deserve individual assessment rather than being treated as equivalent to menopause occurring at the usual age.

Can Lifestyle Changes Lower LDL After Menopause?

Lifestyle remains an important part of cardiovascular prevention.

Dietary patterns that limit saturated fat while emphasising vegetables, fruit, whole grains, fibre and appropriate protein sources can support healthier lipid levels. Regular physical activity, avoiding smoking, managing blood pressure and addressing diabetes or excess weight where relevant also reduce cardiovascular risk. (Menopause Society⁠)

Importantly, lifestyle is not simply a response to weight gain.

A woman can have a body weight she considers normal and still develop elevated LDL.

Conversely, someone can follow a highly health-conscious lifestyle and still have high cholesterol because genetic and biological factors remain important.

Lifestyle should therefore be treated as part of risk management—not a moral explanation for why someone’s cholesterol changed.

Does Menopausal Hormone Therapy Lower Cholesterol?

Menopausal hormone therapy can affect lipid measures, and the effects differ according to formulation and route of administration.

But hormone therapy should not be started primarily to prevent cardiovascular disease or simply to lower LDL cholesterol.

The decision to use menopausal hormone therapy is based principally on appropriate indications such as bothersome menopausal symptoms, together with an assessment of benefits, risks, age, time since menopause and individual medical history.

If elevated LDL requires treatment, cardiovascular risk should be assessed directly rather than assuming hormone therapy will solve the problem.

When Might Medication Be Needed?

Not every elevated LDL result requires cholesterol-lowering medication.

Treatment decisions depend on the degree of LDL elevation and the person’s broader cardiovascular risk.

The 2026 dyslipidemia guideline uses cardiovascular-risk assessment alongside factors such as family history, diabetes, chronic kidney disease, inflammatory conditions and reproductive risk markers. Coronary artery calcium testing and additional biomarkers may be useful in selected people when treatment decisions remain uncertain. (American Heart Association⁠)

Statins remain the foundation of lipid-lowering medication for people who require pharmacological treatment.

Whether medication is appropriate is an individual clinical decision—not something determined by menopause status alone.

When to Seek Medical Assessment

Discuss your cholesterol with a healthcare professional if your LDL is elevated, has increased substantially from previous results, or you have additional cardiovascular risk factors.

Assessment is particularly important with a strong family history of premature cardiovascular disease, diabetes, high blood pressure, kidney disease, smoking history or early menopause.

Very high LDL can also suggest an inherited lipid disorder such as familial hypercholesterolaemia and should not simply be attributed to menopause.

Your clinician may recommend repeat blood testing, broader cardiovascular-risk assessment or treatment depending on the result and your history.

Menopause Is a Cardiovascular Health Checkpoint

Menopause is often discussed through symptoms: hot flashes, sleep disturbance, changing periods, brain fog and vaginal symptoms.

But some of its most important changes may be silent.

LDL cholesterol can rise without causing any symptoms at all.

That makes the menopause transition a useful moment to broaden the conversation from symptom management to long-term health.

The goal is not to make menopause sound like a disease.

It is to recognise that reproductive ageing can change cardiovascular risk—and that identifying those changes creates an opportunity to act before cardiovascular disease develops.

FAQs

Does menopause cause high LDL cholesterol?

Menopause can contribute to increasing LDL cholesterol, particularly during late perimenopause and early postmenopause, but genetics, ageing, lifestyle and other health conditions also influence LDL levels. (professional.heart.org⁠)

Why did my cholesterol suddenly rise during perimenopause?

Hormonal and metabolic changes during the menopause transition can alter lipid metabolism and body composition. Ageing and other cardiovascular risk factors may be occurring simultaneously.

Should I worry about high cholesterol if my HDL is high?

A high HDL result does not automatically cancel the cardiovascular risk associated with elevated LDL or other risk factors. Overall cardiovascular risk should be assessed rather than interpreting one cholesterol measure in isolation. (professional.heart.org⁠)

Can menopause hormone therapy treat high LDL?

Hormone therapy can alter lipid levels, but it is not used primarily as cholesterol-lowering treatment or solely to prevent cardiovascular disease.

Should women have cholesterol checked during perimenopause?

Routine cardiovascular screening should continue throughout adulthood, and perimenopause is a particularly useful time to review cholesterol, blood pressure, blood glucose and other risk factors. (American Heart Association⁠)

Continue on Sistapedia®

For Sistas: Create your free Sistapedia® profile to explore trusted information across menopause, hormonal health and long-term women’s health. Complete free Pink Tick identity verification to participate as a verified Sista and share your experience if you choose.

For healthcare professionals and Experts: Establish your verified professional presence and publish educational content across Sistapedia®. Eligible Medical Doctors, Doctors of Osteopathic Medicine, General Practitioners, Registered Nurses, Healthcare Practitioners and Experts can apply for Crown Verification through the Verification tab in their profile.

Sources

American Heart Association — Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention. (professional.heart.org⁠)

American Heart Association/American College of Cardiology — 2026 Guideline on the Management of Dyslipidemia. (professional.heart.org⁠)

The Menopause Society — Heart Health. (Menopause Society⁠)

2026 analysis reported by the American Heart Association — Perimenopause may offer a “window of opportunity” for heart disease prevention in women. (American Heart Association⁠)

Medical disclaimer: This article provides general educational information and does not replace personalised medical advice, diagnosis or treatment.